Abstracts tagged "Randomized Trial"

Abstract Number: 0287 • ACR Convergence 2022
Association Between Short-Term Response to Upadacitinib Treatment and Long-Term Clinical Outcomes in Patients with Rheumatoid Arthritis and Prior Inadequate Response to Tumor Necrosis Factor Inhibitor Therapy
Christina Charles-Schoeman¹, Roy Fleischmann², Stephen Hall³, Arthur Kavanaugh⁴, Andrea Rubbert-Roth⁵, Ryan DeMasi⁶, Sara Penn⁶, Andrew Garrison⁶, Samuel Anyanwu⁶, Radames Sierra-Zorita⁷ and Ricardo Xavier⁸, ¹Division of Rheumatology, University of California, Los Angeles, Santa Monica, CA, ²University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX, ³Emeritus Research and Monash University, Melbourne, Australia, ⁴University of California San Diego, La Jolla, CA, ⁵Division of Rheumatology, Cantonal Clinic St Gallen, St.Gallen, Switzerland, ⁶AbbVie, Inc., North Chicago, IL, ⁷University of Puerto Rico, San Juan, Puerto Rico, ⁸Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
Background/Purpose: Early predictors of response to treatment with upadacitinib (UPA), an oral Janus kinase inhibitor, could help to optimize a treat-to-target approach in patients with…
Abstract Number: 1424 • ACR Convergence 2022
Cost-Effectiveness of a Progressive Spacing of Tocilizumab or Abatacept in Patients with Rheumatoid Arthritis in Sustained Remission: A Medico-Economic Analysis of the ToLEDo Trial
Joanna KEDRA¹, Lina El Houari¹, Florence Tubach¹, Benjamin granger¹ and Bruno Fautrel², ¹Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, PEPITES, F75013, Paris, France, Paris, France, ²Sorbonne University Paris, France and Pierre Louis Institute of Epidemiology and Public Health, Paris, France, Paris, France
Background/Purpose: Biologic Disease Modifying Anti-Rheumatic Drugs (bDMARDs) progressive tapering is a real opportunity in people living with rheumatoid arthritis (RA) having achieved remission both from…
Abstract Number: 2146 • ACR Convergence 2022
Efficacy of Upadacitinib in Patients with Psoriatic Arthritis and Prior Exposure to Anti-TNF Therapy in the SELECT-PsA 2 Trial Through 2 Years
Philip J Mease¹, Rodrigo Luppino Assad², Shigeyoshi Tsuji³, Pascal Richette⁴, Arathi Setty⁵, Erin McDearmon-Blondell⁶, Tianming Gao⁵, Sandra Ciecinski⁶ and Filip Van den bosch⁷, ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil, ³Department of Orthopaedics and Rheumatology, Nippon Life Hospital, Osaka, Japan, ⁴Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France, ⁵AbbVie, Inc., North Chicago, IL, ⁶AbbVie, Inc., Mettawa, IL, ⁷Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium
Background/Purpose: Patients with psoriatic arthritis (PsA) who experience anti-TNF failure and switch to another TNF inhibitor as second- or third-line therapy typically show poorer responses…
Abstract Number: 0293 • ACR Convergence 2022
Long-term Sustainability of Response to Upadacitinib Among Patients with Active Rheumatoid Arthritis Refractory to Biological Disease-Modifying Anti-Rheumatic Drugs: Results Through 5 Years from SELECT-BEYOND
Ronald van Vollenhoven¹, Stephen Hall², Alvin Wells³, Sebastian Meerwein⁴, Yanna Song⁵, Jessica Suboticki⁶ and Roy Fleischmann⁷, ¹Amsterdam University Medical Centers, Amsterdam, Netherlands, ²Emeritus Research and Monash University, Melbourne, Australia, ³Aurora Rheumatology and Immunotherapy Center, Franklin, WI, ⁴AbbVie Deutschland GmbH & Co KG, LUDWIGSHAFEN, Germany, ⁵AbbVie, Inc., North Chicago, IL, ⁶AbbVie, Inc., Mettawa, IL, ⁷Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: The primary treatment goal for patients with rheumatoid arthritis (RA) is sustained remission (REM), but low disease activity (LDA) is considered an appropriate target…
Abstract Number: 1435 • ACR Convergence 2022
Effectiveness of Combination Therapy with Tocilizumab and Low-Dose Prednisolone as an Induction Therapy in Biologics-Naïve Patients with Rheumatoid Arthritis: A Prospective, Randomized, Controlled, Open-Label, Multicenter Study
Kazuhiro Yokota¹, Hayato Nagasawa², Yuji Akiyama³ and Toshihide Mimura⁴, ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma Saitama, ²Nagasawa Clinic, Kawagoe, Japan, ³Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma Saitama, Japan, ⁴Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: Efficacy and safety of tocilizumab (TCZ) in the treatment of rheumatoid arthritis (RA) has demonstrated in randomized controlled trials. However, the clinical response to…
Abstract Number: 2151 • ACR Convergence 2022
Izokibep Demonstrates Clinically Relevant Efficacy Benefits on Enthesitis, Dactylitis and Nail Outcomes in Active PsA Patients: A 16-week Randomized, Placebo-controlled Trial
Kurt de Vlam¹, Peter Taylor², Philip J Mease³, Paul Peloso⁴, Dieter Wetzel⁵, Nicolai Brun⁵, Brian Wiens⁶, Jan Brandt-Juergens⁷, Edit Drescher⁸, Eva Dokoupilova⁹, Anna Rowinska-Osuch¹⁰, Nadia Abdel- Kader Martin¹¹ and Frank Behrens¹², ¹University Hospitals Leuven, Leuven, Belgium, ²University of Oxford, Oxford, United Kingdom, ³Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ⁴ACELYRIN, Naples, FL, ⁵Affibody AB, Solna, Sweden, ⁶ACELYRIN, Inc., Los Angeles, CA, ⁷Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁸Veszprem Megyei Csolnoky Ferenc Korhaz, Budapest, Hungary, ⁹Medical Plus, s.r.o. & Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Brno, Prague, Czech Republic, ¹⁰ETG Network, Warsaw, Poland, ¹¹Hospital Infanta Luisa Quiron, Rheumatology, Sevilla, Spain, ¹²Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany
Background/Purpose: PsA is a chronic, inflammatory disease with multiple manifestations, with arthritis and skin involvement. Other areas of inflammation include enthesitis, dactylitis and nail involvement.…
Abstract Number: 0294 • ACR Convergence 2022
Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic DMARDs: Results Through 5 Years from the SELECT-BEYOND Study
Roy Fleischmann¹, Sebastian Meerwein², Christina Charles-Schoeman³, BERNARD COMBE⁴, Stephen Hall⁵, Nasser Khan⁶, Kyle Carter⁷, Heidi Camp⁸ and Andrea Rubbert-Roth⁹, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²AbbVie Deutschland GmbH & Co KG, LUDWIGSHAFEN, Germany, ³Division of Rheumatology, University of California, Los Angeles, Santa Monica, CA, ⁴Montpellier University, Montpellier, France, ⁵Emeritus Research and Monash University, Melbourne, Australia, ⁶AbbVie, Inc., Abbott Park, IL, ⁷AbbVie, Inc., North Chicago, IL, ⁸Abbvie, Winnetka, IL, ⁹Division of Rheumatology, Cantonal Clinic St Gallen, St.Gallen, Switzerland
Background/Purpose: To evaluate the long-term efficacy and safety of upadacitinib (UPA) over 5 yrs among patients with rheumatoid arthritis (RA) in a long-term extension (LTE)…
Abstract Number: 1579 • ACR Convergence 2022
The TICOG Study: Tight Control of Gout – A Randomized, Controlled Trial of Targeted versus Conventional Treatment for Gout Including Ultrasonography
Sarah Black, Natalie McKee, Jonathan McKnight, Annmarie McShane, Adrian Pendleton, Taggart Alister and Gary Wright, Musgrave Park Hospital, Belfast Health and Social Care Trust, Belfast, Northern Ireland, United Kingdom
Background/Purpose: Gout is a common inflammatory arthritis triggered by deposition of monosodium urate crystals in joints, bone and soft tissues, with a prevalence of 1-4%…
Abstract Number: 2188 • ACR Convergence 2022
The Effect of Group-based Cognitive Behavioral Therapy for Insomnia in People with Rheumatoid Arthritis: A Randomized Controlled Trial
Kristine Latocha¹, Katrine Loeppenthin², Mikkel Østergaard³, poul jennum⁴, Merete L Hetland⁵, Henrik Rogind⁶, Tine Lundbak⁶, Julie Midtgaard⁷, Robin Christensen⁸ and Bente Esbensen⁵, ¹Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark, ²Department of Oncology, Copenhagen University Hospital - Rigshospitalet, Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, ³Rigshospitalet, University of Copenhagen, Glostrup, Denmark, ⁴Danish Center for Sleep Medicine, Department of Clinical Neurophysiology, Copenhagen University Hospital - Rigshospitalet, Glostrup,Department of Clinical Medicine, University of Copenhagen, Copenhagen, ⁵Rigshospitalet, Glostrup, Denmark, ⁶Center for Rheumatology and Spine Diseases, Copenhagen University Hospital -Rigshospitalet, Glostrup, Denmark, ⁷Mental Health Centre Glostrup, University of Copenhagen, Glostrup,Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, ⁸Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark
Background/Purpose: Insomnia is highly prevalent in people with rheumatoid arthritis (RA) and may exacerbate symptoms and burdens, such as fatigue, depressive symptoms, and pain (1).…
Abstract Number: 0295 • ACR Convergence 2022
Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic DMARDs: Results Through 5 Years from the SELECT-NEXT Study
Gerd Burmester¹, Filip Van den bosch², John Tesser³, Anna K Shmagel⁴, Yuanyuan Duan⁴, Nasser Khan⁵, Heidi Camp⁶ and Alan Kivitz⁷, ¹Charité University Medicine Berlin, Berlin, Germany, ²Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium, ³Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ⁴AbbVie, Inc., North Chicago, IL, ⁵AbbVie, Inc., Abbott Park, IL, ⁶Abbvie, Winnetka, IL, ⁷Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: In the phase 3 SELECT-NEXT study, upadacitinib (UPA) demonstrated efficacy at wk 12 and sustained efficacy up to wk 60 in patients with rheumatoid…
Abstract Number: 1597 • ACR Convergence 2022
Achievement of Different Treatment Targets with Izokibep Demonstrates Efficacy Benefits in Patients with Active Psoriatic Arthritis: Results from a 16-Week Randomized, Placebo-Controlled Phase 2 Clinical Trial
Frank Behrens¹, Peter Taylor², Philip J Mease³, Paul Peloso⁴, Dieter Wetzel⁵, Nicolai Brun⁵, Brian Wiens⁶, Jan Brandt-Juergens⁷, Edit Drescher⁸, Eva Dokoupilova⁹, Anna Rowińska-Osuch¹⁰, Nadia Abdel- Kader Martin¹¹ and Kurt de Vlam¹², ¹Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, ²University of Oxford, Oxford, United Kingdom, ³Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ⁴ACELYRIN, Naples, FL, ⁵Affibody AB, Solna, Sweden, ⁶ACELYRIN, Inc., Los Angeles, CA, ⁷Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁸Veszprem Megyei Csolnoky Ferenc Korhaz, Budapest, Hungary, ⁹Medical Plus, s.r.o. & Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Brno, Prague, Czech Republic, ¹⁰ETG Network - Rheumatology, Warsaw, Poland, ¹¹Hospital Infanta Luisa Quiron, Rheumatology, Sevilla, Spain, ¹²University Hospitals Leuven, Leuven, Belgium
Background/Purpose: Psoriatic arthritis (PsA) is a chronic, inflammatory disease with multiple clinical manifestations (arthritis, spondylitis, enthesitis, dactylitis, skin, nails). IL-17 inhibitors have shown efficacy across…
Abstract Number: 2209 • ACR Convergence 2022
Efficacy of Secukinumab in Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis Subtypes of Juvenile Idiopathic Arthritis: Results from a Randomized, Phase 3 Study
Hermine Brunner¹, Elena Chertok², Joke Dehoorne³, Gerd Horneff⁴, Tilmann Kallinich⁵, Ingrid Louw⁶, Maria Alessio⁷, Sandrine Compeyrot-Lacassagne⁸, Bernard Lauwerys⁹, Neil Martin¹⁰, Katherine Marzan¹¹, W Patrick Knibbe¹², Ruvie Martin¹³, Xuan Zhu¹⁴, sarah whelan¹⁵, Luminita Pricop¹⁶, Daniel Lovell¹⁷, Alberto Martini¹⁸ and Nicola Ruperto¹⁹, ¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Department of Pediatrics, Cincinnati, OH, ²Voronezh State Medical University, Voronezh, Russia, ³University Hospital Gent, Gent, Belgium, ⁴Pediatrics, Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, ⁵Charité - Universitätsmedizin Berlin, Nuremberg, Germany, ⁶Panaroma Medical Centre, Cape Town, South Africa, ⁷Policlinico Federico II di Napoli, Napoli, Italy, ⁸Great Ormond Street Hospital for Children, London, United Kingdom, ⁹Cliniques Universitaires Saint-Luc, Brussels, Belgium, ¹⁰Royal Hospital for Children, Glasgow, Scotland, United Kingdom, ¹¹Children's Hospital Los Angeles, Los Angeles, CA, ¹²St. Luke's Hospital System, Meridian, ID, ¹³Novartis Pharmaceutical Corporation, East Hanover, NJ, ¹⁴Novartis Pharmaceuticals Corporation, Basking Ridge, NJ, ¹⁵Novartis Ireland Ltd, Crumlin, Dublin, Ireland, ¹⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁷Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁸Istituto Giannina Gaslini, Genova, Italy, ¹⁹IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy
Background/Purpose: Juvenile idiopathic arthritis (JIA) categories of enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) represent pediatric counterparts of adult non-radiographic axial spondyloarthritis and psoriatic…
Abstract Number: 0307 • ACR Convergence 2022
Reduction in Structural Damage Progression and Improvement in Clinical Response with Abatacept Treatment in Patients with ACPA+, Early RA: Results from a Post Hoc Analysis of the AVERT-2 Study by Baseline Erosion Scores
Chahin Pachai¹, Sean E Connolly², Yoshiya Tanaka³, Vivian Bykerk⁴, Tom Huizinga⁵, Gustavo Citera⁶, Clifton O. Bingham III⁷, Shuyan Du¹, Godehard Hoexter⁸, Roy Fleischmann⁹, Subhashis Banerjee¹ and Paul Emery¹⁰, ¹Bristol Myers Squibb, Princeton, NJ, ²Bristol-Myers Squibb, Morrisville, PA, ³University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ⁴Hospital for Special Surgery, New York, NY, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Instituto de Rehabilitación Psicofísica (IREP), Buenos Aires, Argentina, ⁷Johns Hopkins University, Baltimore, MD, ⁸Bristol Myers Squibb GmbH & Co. KGaA, Munich, Germany, ⁹University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX, ¹⁰Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Presence of structural damage is an important risk factor for further damage progression over time in RA. Inhibition of damage progression is a key…
Abstract Number: 1603 • ACR Convergence 2022
Intervention with Methotrexate in Arthralgia at Risk for Rheumatoid Arthritis to Reduce the Development of Persistent Arthritis and Its Disease Burden (TREAT EARLIER): A Double-blind, Randomized, Placebo-controlled Trial
Doortje Krijbolder¹, Marloes Verstappen¹, Bastiaan van Dijk², Yousra Dakkak¹, Aleid Boer¹, Yune-Jung Park¹, Marianne E. de Witt-Luth³, Karen Visser⁴, Marc Kok⁵, Esmeralda T.H. Molenaar⁶, Pascal de Jong⁷, Stephan Böhringer⁸, Tom Huizinga¹, CF Allaart¹, Ellis Niemantsverdriet⁹ and Annette van der Helm-van Mil¹⁰, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Centre (LUMC), Leiden, Netherlands, ³Reinier de Graaf Ziekenhuis, Delft, Netherlands, ⁴Haga Ziekenhuis, Amsterdam, Netherlands, ⁵Department of Rheumatology and Clinical immunology, Maasstad Hospital, Rotterdam, Netherlands, ⁶Groene Hart Ziekenhuis, Gouda, Netherlands, ⁷ErasmusMC, Hendrik Ido Ambacht, Netherlands, ⁸Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, Leiden, Netherlands, ⁹LUMC, Leiden, Netherlands, ¹⁰Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is the most common autoimmune disease and requires long term treatment to suppress inflammation. Currently, treatment is started when arthritis is…
Abstract Number: 2243 • ACR Convergence 2022
Patient Reported Outcomes from a Randomized Phase 3 Trial of Sarilumab in Polymyalgia Rheumatica
Vibeke Strand¹, Jennifer Sloane Lazar², Michael C Nivens³, Jingdong Chao⁴, Stefano Fiore⁵, Angeliki Giannelou⁶, Lita Araujo⁷ and Jerome Msihid⁸, ¹Stanford University School of Medicine, Stanford, CA, ²Sanofi, Delray Beach, FL, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY, NY, ⁴Regeneron Pharmaceuticals, Inc.,, Tarrytown, NY, ⁵Sanofi, Bridgewater, NJ, ⁶Regeneron Pharmaceuticals, Inc., Hoboken, NJ, ⁷Sanofi, Cambridge, MA, ⁸Sanofi, Chilly-Mazarin, France
Background/Purpose: Polymyalgia rheumatica (PMR) is a common inflammatory rheumatic disease in the elderly. The phase 3 SAPHYR trial (NCT03600818) assessed the efficacy and safety of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].